Paradigm Partners with Advanced Clinical for Pivotal Phase III Osteoarthritis Trial
核心洞察
Paradigm Biopharmaceuticals (搜索) has selected Advanced Clinical (搜索) as their CRO partner for PARA_OA_012 (搜索), a Phase III trial evaluating injectable pentosan polysulfate sodium for knee osteoarthritis (搜索) pain.
The double-blind, multi-center study aims to enroll 466 subjects, with an interim analysis planned after day 112, building on promising Phase II results showing significant pain reduction.
Trial initiation is scheduled for Q2 2025 across ten Australian sites, pending ethics approval, with initial sites being activated in Victoria.
Paradigm Biopharmaceuticals (搜索) has taken a significant step forward in its osteoarthritis (搜索) research program by selecting Advanced Clinical (搜索) as the clinical research organization (CRO) to oversee its pivotal Phase III trial, PARA_OA_012 (搜索). The partnership emerged following a comprehensive evaluation of seven global CROs, with Advanced Clinical distinguished by its strategic alignment and specialized capabilities in osteoarthritis research.
The upcoming Phase III trial will evaluate injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis (搜索) pain through a rigorous double-blind, multi-center, placebo-controlled study. The trial design includes a planned enrollment of 466 subjects, with a strategic interim analysis scheduled after day 112 using pain data from approximately half of the participants.
Trial Design and Scientific Foundation
The PARA_OA_012 (搜索) study builds upon encouraging results from previous Phase II investigations, particularly the PARA_OA_008 (搜索) trial, which demonstrated significant pain reduction and improved joint function in patients treated with iPPS. These benefits were observed to persist for up to 12 months, establishing a strong foundation for the Phase III program.
Paul Rennie, Managing Director of Paradigm Biopharmaceuticals (搜索), expressed enthusiasm about the collaboration: "Advanced Clinical (搜索)'s expertise in clinical trial execution, regulatory strategy, and patient engagement makes it an ideal partner for Paradigm as we execute the pivotal Phase III osteoarthritis (搜索) trial. With global capabilities and a strong track record in OA research, Advanced Clinical will support Paradigm in delivering a seamless trial, ensuring regulatory success, and accelerating the development of transformative therapies."
Implementation Timeline and Site Activation
The trial's operational phase is set to commence following pending ethics approval in Australia. Initial site activation will begin in Victoria, with plans to expand to up to ten sites across the country. The company anticipates dosing the first subject in the second quarter of 2025, marking a crucial milestone in the development of this potential therapeutic option for osteoarthritis (搜索) patients.
Strategic Significance
This partnership represents a critical advancement in addressing the significant unmet need in osteoarthritis (搜索) treatment. The selection of Advanced Clinical (搜索), following their standout performance among four shortlisted CROs, positions the trial for optimal execution and data quality. Their proven expertise in osteoarthritis research and comprehensive clinical trial management capabilities align well with the study's objectives and complexity.